These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2672607)

  • 21. Clinical tumour markers in ovarian cancer.
    Mazurek A; Nikliński J; Laudański T; Pluygers E
    Eur J Cancer Prev; 1998 Feb; 7(1):23-35. PubMed ID: 9511849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular biology of human ovarian cancer.
    Chow SN; Chien CH; Chen CT
    Int Surg; 1996; 81(2):152-7. PubMed ID: 8912082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular prognostic markers in pancreatic cancer.
    Ghaneh P; Kawesha A; Evans JD; Neoptolemos JP
    J Hepatobiliary Pancreat Surg; 2002; 9(1):1-11. PubMed ID: 12021893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
    Spandidos DA
    Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic characterization of tumor markers in human ovarian cancer cell lines.
    Kutteh WH; Miller DS; Mathis JM
    J Soc Gynecol Investig; 1996; 3(4):216-22. PubMed ID: 8796833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What are tumor markers, and what is their value?].
    von Kleist S
    Wien Klin Wochenschr; 1989 Jul; 101(14):459-63. PubMed ID: 2672605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of transforming growth factor alpha TGF-alpha) in human lung carcinoma: an immunohistochemical study.
    Pecur L; Kapitanovic S; Sonicki Z; Pavicic F; Spaventi S; Gluckman JL; Stambrook PJ; Pavelic ZP; Spaventi R; Pavelic K
    Anticancer Res; 1994; 14(6B):2839-43. PubMed ID: 7872728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
    Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
    Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour markers - new aspects of an old discussion?
    Fleischhacker M; Beinert T
    Eur J Med Res; 1999 Apr; 4(4):144-8. PubMed ID: 10205289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular markers of ovarian carcinoma].
    Dobryszycka W
    Postepy Hig Med Dosw; 2000; 54(4):495-518. PubMed ID: 11016269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Basic concepts in the use of tumor markers in the diagnosis and follow-up of malignant bladder neoplasms].
    Moreno Sierra J; Gómez Ruiz JJ; Ortega Heredia MD; Blanco Jiménez E; Silmi Moyano A; Blázquez Izquierdo J; Corral Rosillo J; Rodríguez Molina J; Ramírez Fernández JC; Resel Estévez L
    Arch Esp Urol; 1993 Apr; 46(3):187-98. PubMed ID: 8512354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of tumour markers in cancer diagnosis and treatment.
    Higgins C
    Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
    Duda DG; Sunamura M; Lefter LP; Furukawa T; Yokoyama T; Yatsuoka T; Abe T; Inoue H; Motoi F; Egawa S; Matsuno S; Horii A
    Oncogene; 2003 Oct; 22(44):6857-64. PubMed ID: 14534532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tumor-associated and epithelial markers in gastrointestinal tumors].
    Knuth A; Klingel R; Moll R; Dippold W; Meyer zum Büschenfelde KH
    Verh Dtsch Ges Inn Med; 1991; 97():414-9. PubMed ID: 1725565
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical application of oncogene and antioncogene as a tumor marker].
    Kondo H; Nobuoka A
    Nihon Rinsho; 1996 Jun; 54(6):1494-8. PubMed ID: 8691599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The development of immunoscintigraphy into a routine method].
    Pateisky N
    Wien Klin Wochenschr; 1990 Aug; 102(15):424-6. PubMed ID: 2205987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Usefulness of the chosen tumor markers at diagnostics and monitoring the treatment].
    Zielińiska K; Karczmarek-Borowska B
    Przegl Lek; 2013; 70(11):986-90. PubMed ID: 24697044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.